← Entrada Therapeutics, Inc. (TRDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Entrada Therapeutics, Inc. (TRDA)
Pharmaceutical Preparations · market cap $250M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Entrada Therapeutics (TRDA) is a small-cap pharma (~$284M market cap, 183 employees) focused exclusively on Duchenne Muscular Dystrophy, with two Phase 2 assets — ENTR-601-44 and ENTR-601-45 — targeting this rare pediatric disease. The company is in a critical financial position with only $76.4M in cash and a stated runway of approximately 5.5 months, making near-term capital raising or a partnership essentially mandatory for survival.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ENTR-601-44 | Phase 2 | Duchenne Muscular Dystrophy (DMD) |
| ENTR-601-45 | Phase 2 | Duchenne Muscular Dystrophy (DMD) |
Price & technical context
3-month
-26.4%
6-month
-57.9%
12-month
-2.1%
52-wk range
$5.65–$16.03
vs 50-day MA
-17.5%
vs 200-day MA
-39.3%
Realized vol
106.6%
Max drawdown
-76.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TRDA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.